source
- CellCentric raises $220M to get multiple myeloma pill to marketCellCentric has reeled in a massive fund to help it address multiple myeloma patients who have exhausted all other treatment options. The 22-year-old transatlantic biotech has collected a $220 mill…Endpoints · 2mo ago↗ source
- Bayer to buy Perfuse Therapeutics for $300M upfrontBayer is committing $300 million upfront to buy ophthalmology biotech Perfuse Therapeutics and its mid-stage program targeting the leading causes of blindness. The deal appears to be Bayer’s first…Endpoints · 2mo ago↗ source
- Novo Nordisk's Q1 in four words: Pills, pricing, payments and pressureA million patients with obesity are already taking Novo Nordisk’s Wegovy pill, CEO Mike Doustdar said Wednesday, despite the market entry of Lilly’s Foundayo. Novo's pill had sales of 2.3 billion D…